Early Detection and Prognosis of Patients with Hepatocellular Carcinoma

肝细胞癌患者的早期检测和预后

• 批准号: 7361367
• 负责人: JORGE A MARRERO
• 金额: $ 7.45万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7361367
• 关键词: Accounting; Alcohols; Award; Biological Markers; Cancer Etiology; Caring; Case-Control Studies; Cessation of life; Cirrhosis; Classification; Clinical Research; Cohort Studies; Common Neoplasm; Data; Death Rate; Development; Diagnosis; Diagnostic Neoplasm Staging; Early Diagnosis; Etiology; Evaluation; Evaluation of Risk Factors; Funding; Guidelines; Hepatic; Image; Incidence; Liver diseases; Malignant Neoplasms; Malignant neoplasm of liver; Measures; Medical; Mentored Clinical Oncology Award; Mentored Clinical Scientist Award; Mentored Patient-Oriented Research Career Development Award; Methods; National Cancer Institute; Obesity; Patients; Performance Status; Personal Satisfaction; Primary carcinoma of the liver cells; Prognostic Factor; Prospective Studies; Publishing; Research; Research Personnel; Retrospective Studies; Risk; Risk Factors; Staging; Staging System; Time; Tobacco; Tumor Burden; Tumor Markers; Tumor stage; alpha-Fetoproteins; base; case control; cohort; demographics; improved; liver function; novel; outcome forecast; prognostic; prospective; trial comparing; tumor

DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the 5th most common tumor and the 3rd most common cause of cancer death worldwide. In the U.S.A., it is the tumor with the largest increase in incidence over the last 10 years. The incidence and death rates are similar indicating the overall poor survival of HCC. Therefore, strategies to improve the early detection and to identify those at the highest risk are of paramount importance. For the K23 award I indicated I would do 2 studies: a case-control study of patients with HCC and cirrhosis as controls, and a prospective cirrhotic cohort study. The aims were to evaluate new tumor markers for the detection of early HCC and to identify risk factors for the development of HCC. The multicenter case-control is nearing completion, and accrual for the prospective study is well. In this proposal, there will be 2 aims: 1) is the evaluation of risk factors for the development of HCC and novel biomarkers for the early detection of HCC, and 2) the prospective evaluation of the prognosis of patients with HCC. We recently published the largest trial comparing the staging systems of HCC, and found that the Barcelona Staging systems was the best at determining prognosis of patients with HCC because it takes into account liver function, tumor burden and performance status. For the remainder of the R03, I plan to continue the prospective cohort study of patients with cirrhosis when they are seen for their routine medical care every 6 -12 months, which is based on national guidelines. I also plan to follow patients with HCC after their diagnosis at designated intervals (6weeks initially then every 2 months thereafter) to study the prognostic factors of patients with HCC and to prospectively validate the Barcelona Staging system. At the end of the K23 and R03, I will have the preliminary data for an R01 submission and more importantly, I will be on my way to being an independent investigator. Liver cancer is the 5th most common tumor and the 3rd most common cause of cancer death worldwide. Over the last 10 years, liver cancer has the largest increase in new tumors compared to all other cancers. Therefore, identifying the risk factors, identifying new methods for early detection and determining prognosis for this tumor is of extreme importance.

描述（由申请人提供）： 肝细胞癌 (HCC) 是全球第五大常见肿瘤，也是全球第三大癌症死亡原因。在美国，它是过去 10 年来发病率增幅最大的肿瘤。发病率和死亡率相似，表明 HCC 的总体生存率较差。因此，改善早期检测和识别高风险人群的策略至关重要。对于 K23 奖，我表示我将进行两项研究：一项以 HCC 和肝硬化患者为对照的病例对照研究，以及一项前瞻性肝硬化队列研究。目的是评估用于检测早期 HCC 的新肿瘤标志物并确定 HCC 发展的危险因素。多中心病例对照已接近完成，前瞻性研究的效果良好。该提案有两个目标：1）评估HCC发生的危险因素和早期检测HCC的新生物标志物，2）对HCC患者的预后进行前瞻性评估。我们最近发表了比较 HCC 分期系统的最大规模试验，发现巴塞罗那分期系统最适合确定 HCC 患者的预后，因为它考虑了肝功能、肿瘤负荷和体能状态。对于 R03 的剩余时间，我计划继续对肝硬化患者每 6 -12 个月进行一次常规医疗护理进行前瞻性队列研究，该研究基于国家指南。我还计划在诊断后按照指定的时间间隔（最初 6 周，然后每 2 个月）对 HCC 患者进行随访，以研究 HCC 患者的预后因素并前瞻性验证巴塞罗那分期系统。在 K23 和 R03 结束时，我将获得 R01 提交的初步数据，更重要的是，我将走上成为一名独立调查员的道路。 肝癌是全球第五大常见肿瘤，也是第三大癌症死亡原因。过去10年里，与所有其他癌症相比，肝癌的新发肿瘤增幅最大。因此，识别该肿瘤的危险因素、确定早期检测和确定预后的新方法极其重要。

项目成果

Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.

• DOI: 10.1158/1055-9965.epi-11-1005
• 发表时间: 2012-05
• 期刊: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
• 作者: Singal AG;Conjeevaram HS;Volk ML;Fu S;Fontana RJ;Askari F;Su GL;Lok AS;Marrero JA
• 通讯作者: Marrero JA

Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.

• DOI: 10.1038/ajg.2013.332
• 发表时间: 2013-11
• 期刊: The American journal of gastroenterology
• 作者: Singal AG;Mukherjee A;Elmunzer BJ;Higgins PD;Lok AS;Zhu J;Marrero JA;Waljee AK
• 通讯作者: Waljee AK

Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

• DOI: 10.1111/j.1365-2036.2009.04014.x
• 发表时间: 2009-07
• 期刊: Alimentary pharmacology & therapeutics
• 影响因子: 7.6
• 作者: Singal A;Volk ML;Waljee A;Salgia R;Higgins P;Rogers MA;Marrero JA
• 通讯作者: Marrero JA